Summary. -Accurate and timely detection of drug-associated viral mutants is important during antiviral therapy. Combining Smart Amplifi cation Process (SMAP) with competition probe, an assay specifi cally designed to detect point mutation at codon 204 of the hepatitis B virus (HBV) polymerase gene was developed. Th is assay was sensitive to detect 20 copies of mutant/reaction and recognize as little as 1% of minor mutants in the viral population. Th e comparison of direct sequencing and SMAP method on 35 clinical specimens showed the concordance in 88% of the cases. Th is method provides an effi cient alternative for rapid identifi cation of HBV mutation associated with lamivudine resistance. 
Introduction
Over the past decade, a remarkable progress has been made in the effectiveness of the nucleoside/nucleotide analogs in suppressing HBV infection (Iloeje et al., 2007) . Under the selection pressure generated by the presence of an antiviral agent, however, viruses with a mutation that confers a replication advantage are selected and eventually become the predominant viral species (Ghany and Doo, 2009 ). Because of this, the long-term therapy with nucleotide analogs is associated with the development of antiviral drug resistance (Lok et al., 2003; Liaw et al., 2004) . Th e emergence of drug resistance becomes a major challenge in the era of antiviral therapy.
As one of the primary antiviral agents, lamivudine is the fi rst oral nucleoside analogue approved for the treatment of chronic hepatitis B (Reinis et al., 2001) . Resistance to lamivudine occurs rapidly and aff ects 24% and 70% of chronic carriers aft er 1 and 5 years of therapy, respectively . Th e principal mutations identifi ed in HBV as a result of lamivudine treatment are located at codon 204, within the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the virus reverse transcriptase, leading to the replacement of methionine (M) by valine (V) or isoleucine (I) (rtM204V/I) (Ghany and Liang, 2007) .
Methodological options for detecting mutations are an increasingly important issue in HBV clinical management (Kim et al., 2008) . Direct sequencing is the gold method. However, the sensitivity of direct sequencing-based methods is limited, since it is only capable of detecting mutations present in viral quasispecies with a prevalence of ≥20% of the total HBV population (Lok et al., 2007) . To date, a number of other techniques have been reported for detecting druginduced mutations of HBV (Yeon, 2008) , such as restriction fragment length polymorphism (Jardi et al., 1999; Hosseini et al., 2006) , oligonucleotide microarray technology (Li et al., 2005) , selective real-time PCR (Lupo et al., 2009) , matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (Kim et al., 2005) , as well as pyrosequencing (Lindstrom et al., 2004; Margeridon-Th ermet et al., 2009; Solmone et al., 2009) . However, these technologies are still relatively time consuming, complicated, and expensive for routine screening. Since drug resistant viral mutants are usually identifi ed aft er several months of drug treatment with re-elevation of serum HBV DNA levels and fl are-ups of serum transaminase levels, it is important to establish a method to detect the lamivudine-resistant HBV mutant as early as possible, when the mutant virus is still a minor fraction of the total HBV population.
SMAP is a novel approach that can detect single nucleotide polymorphism with a high sensitivity and specifi city under isothermal conditions . Th is method has been successfully used in the mutation detection of human genes (Watanabe et al., 2007; Hoshi et al., 2007; Aomori et al., 2009; Inoue et al., 2009; Araki et al., 2010) . In this study, we tested the applicability of SMAP method to detect tyrosine-valine-aspartate-aspartate (YVDD) mutant virus. Th e main goal of the research was to develop a reliable and cost-eff ective method for rapid screening of drug-resistant viral mutations.
Materials and Methods
Serum samples. Th irty-fi ve samples, obtained from the patients receiving lamivudine therapy to treat chronic HBV infection, were included in the study. Patients enrolled in this study had been hepatitis B surface antigen-positive for 6 months or longer and had elevated ALT values, with HBV DNA levels greater than 20,000 copies/ml before commencement of lamivudine therapy. Neither of these patients was positive for anti-hepatitis C virus antibody or anti-human immunodefi ciency virus antibody (ELISA, KeHua Bio-Engineering Co., Ltd, China). Informed consent was obtained from all patients, and the appropriate institutional review board approved the study.
Real-time PCR for HBV DNA. HBV DNA was extracted from a 50 μl sample by using extraction reagents of the commercially available HBV DNA real-time PCR detection kit (DaAn BioEngineering Co. Ltd., P.R. China), as per the manufacturer΄s instructions. HBV DNA levels were determined by DaAn TaqMan real-time PCR assay, with a detection limit of 3 log copies/ml.
Construction of YMDD and YVDD plasmids. To assess SMAP on well-characterized material, previously sequenced clinical samples harboring the rtM204V mutation and the wt were used as templates for plasmid cloning. PCR products were amplifi ed using forward primer 5ʹ-GTATGTTGCCCGTTTGTCCTC-3ʹ (459-479 nt) and reverse primer 5ʹ-AGCAAACACTTGGC AGAGACC-3ʹ (1168-1188 nt). Samples were amplifi ed in a 50 μl reaction containing 5 μl of 10× buff er (TaKaRa, Japan), 4 mmol/l MgCl 2 , 200 μmol/l each dNTP, 0.2 μmol/l each primer, 1.5 U Hot Start Taq DNA polymerase and 2 μl of template DNA. Aft er an initial denaturation for 5 mins at 95°C there followed 40 cycles of 95°C for 45 secs, 58°C for 1 min, and 72°C for 2 mins. A fi nal cycle with an elongation step of 10 mins at 72°C was included at the end. Th e PCR products were purifi ed by PCR purifi cation kit (Axygen, USA), and inserted into pMD ® 18-T Vector using the TA Cloning kit (TaKaRa, Japan) according to the manufacturer΄s instructions. Aft er the multiplication in E. coli DH5a, plasmids were extracted using the MiniBEST Plasmid Purifi cation Kit (TaKaRa, Japan) and analyzed by direct sequencing to confi rm the presence of the expected mutations. DNA plasmids were then quantifi ed by SMA1000 UV Spectrophotometer (Merinton, China).
Sequencing. Th e sequencing assay was adapted from Vincenti et al. (2009) with slight modifi cations. Th e fi rst-round of nested PCR was performed using forward primer 5ʹ-CCTGCTGG TGGCTCCAGTT-3ʹ (56-74 nt), and reverse primer 5ʹ-CRTCA GCAAACACTTGGC-3ʹ (1175-1192 nt). Th e second-round PCR was performed using forward primer 5ʹ-CTCGTGGTGGAC TTCTCTC-3ʹ (253-271 nt), and reverse primer 5ʹ-GCAAANC CCAAAAGACCCAC-3ʹ (1000-1019 nt). Amplifi cation conditions for both the fi rst and the second rounds were the same as those used for the plasmid cloning. Purifi ed PCR products were sequenced using the primers similar to the second round of PCR, according to the manufacturer's instruction of the Amersham Chemistry DYEnamic ET Terminator Sequencing Kit (Amersham Biosciences, USA).
SMAP assay. A SMAP primer set, including the turn-back primer (TP), the folding primer (FP), the boost primer (BP), and two outer primers (OP1 and OP2), suitable to detect allele-specifi c amplifi cation by SMAP was designed using Primer3 soft ware. For suppression of the background amplifi cation, the 3ʹ-end of FP and the 5ʹ-end of TP were both used to recognize the point mutation. In addition, a competition probe (CP) competing with the FP/ TP on initial hybridization events for generating the intermediate products was designed. Th e primer set was selected as follows: OP1: 5ʹ-TAGTGCCATTTGTTCAGTG-3ʹ, OP2: 5ʹ-ACCCAAA GACAAAAGAAAAT-3ʹ, FP: 5ʹ-GCGAGTCGCTGTTTGGCT TTCAGTTATGTG-3ʹ, BP: 5ʹ-GGCCAAGTCTGTACAACATCT-3ʹ, TP: 5ʹ-TGTGGATGATACAGCGGTAAAAAGGGAC-3ʹ and CP: 5ʹ-GGCTTTCAGTTATATGGATGATGT-NH2-3ʹ.
SMAP assays were carried out in a total of 20 μl reaction mixture containing 2 μmol/l each of FP and TP, 0.25 μmol/l each of OP1 and OP2, 1 μmol/l BP, 1.4mmol/l dNTP, 1 mol/l Betaine, 20 mmol/l Tris-HCl (pH 8.0), 10 mmol/l KCl, 10 mmol/l (NH4) 2 SO 4 , 8 mmol/l MgCl 2 , 0.1% Tween® 20, 1/100,000 diluted original SYBR Green I, 8 U of Bst DNA polymerase (New England Biolabs, USA), 1 μl of template DNA. In cases where CP was used, its concentration ranging from 5-12.5 μmol/l in the reaction mixture was tested. SMAP reactions were performed at 60°C and DNA amplifi cation was monitored using a real time PCR instrument, the Opticon System (Biorad, USA). Aft er amplifi cation, the products of the SMAP reaction were cleaved by Bsp14071 (Fermentas, LTU) and run on a 1.8% agarose gel for sizing and comparison.
Results

Testing of CP in the SMAP assay
A general rule to distinguish the wild from mutant strains is to use primers mismatching the wt strain template, which signifi cantly compromises its amplifi cation. At the same time, the mutant strain is selectively amplifi ed by primers perfectly matching with the mutated template. (Lupo et al., 2009) . Th e autocycling amplifi cation of SMAP is mostly mediated by the function of FP and TP (Kawai et al., 2008) . For this purpose, the base corresponding to the point mutation at both the 3ʹ-end of the FP, and the 5ʹ-end of TP was used to discriminate the target. Th ough 3 bp overlapping between the critical ends of these two self-priming primers exists, the exponential background amplifi cation from mispriming occurs frequently in the preliminary assay (Fig. 1) . To minimize false positives derived from non-target misamplifi cation, strategy using the CP was adopted. CP was designed to compete with the self-priming elongation site on the intermediate product generated from FP or TP.
To optimize the concentration of CP, YMDD plasmids with the concentration of 10
6 copies/ml were tested in the presence of CP with the level ranging from 0~250 pmol/μl. Th e amplifi cation of YMDD strains was totally inhibited in SMAP with more than 150 pmol/μl of CP. When using YVDD plasmid as a template, the amplifi cation time was delayed with increasing CP concentration. Th ese results indicated that using CP that has complete homology to the wt sequence is an eff ective way to suppress the background. CP with the concentration of 150 pmol/μl was used in the following assays.
Specifi city and sensitivity of the SMAP assay
After SMAP reaction, the amplified products were detected by eletrophoresis. The results showed the specific ladder-like pattern that is similar to the hairpin induced isothermal amplification technology (Ren et al., 2009) . No amplification was obtained for the YMDD sample and the blank control. To confirm the accuracy of the specific amplicon by SMAP reaction, Bsp1407 I restriction analysis followed by electrophoresis was performed. As expected, the amplification products digested by Bsp1407 I confirmed that the correct target sequence had been amplified (Fig. 2) .
Tenfold dilutions (10 7 to 10 1 copies/ml) of YVDD plasmid were used as standards to test the sensitivity on the real-time PCR platform. As shown in Fig. 3a , SMAP reaction rapidly amplifi es (less than 30 mins) the YVDD mutants at the concentration of 10 3 to 10 7 copies /ml, whereas the same system was incapable of amplifying wt YMDD strains even aft er 60 mins. A "no-template" control reaction was also negative aft er 60 mins. Each assay was done in duplicate. Th e limit of the detection was 10 3 copies/ml, about 20 copies/reaction. Melting curves for the products were obtained aft er SMAP amplifi cation for 60 mins and detected using 0.2°C steps, and a hold of 1 sec at each step from 65 to 93°C. All isolates had a melting temperature (Tm) of ~85.6°C, indicating similar sequences, and hence similar amplicon. To test the SMAP assay for the capability of diff erentiating limited mutants in a background of wt HBV strain, the YMDD and YVDD plasmids were mixed at a ratio of 100:0, 10:90, 1:99, or 0:100, corresponding to a fi nal concentration of 10 5 copies. Similar results were obtained with all of the mutant plasmids tested. As shown in Fig. 3c , SMAP assay clearly identifi ed 1000 copies of YVDD mutant plasmid in a background of 10 5 copies of heterogeneous plasmid. Th ese results suggested that the level of sensitivity of YVDD variant present in the mixture was 1%.
Testing of the SMAP assay on clinical samples
Th e YVDD-resistant status of the HBV was examined in 35 samples from the patients receiving lamivudine therapy. By using both SMAP assay and direct sequencing in these samples, the two methods gave concordant results (i.e., presence or absence of a mutated strain) in 88% of the cases. In the four samples, the SMAP assay detected the presence of the rtM204V mutation, whereas the direct sequencing assay showed only the YMDD virus. Further sequencing aft er TA cloning was performed to evaluate the discordant results. Th ree of these samples were shown to consist of a mixture of viruses. For the remaining case, SMAP assay displayed exponential kinetics of the amplifi cation profi le, but with a long delay in appearance when compared to the profi le of the sample with similar concentration. Aft er subcloning, 10 randomly picked clones were sequenced and showed to be pure wt.
Discussion
Management of antiviral resistance has been well shaped in recent years (Fournier and Zoulim, 2007; Ghany and Doo, 2009 ). One concept is that the rescue therapy should be initiated at the time of virologic breakthrough, which is defi ned as a 10-fold increase in serum HBV DNA from nadir during the treatment in a patient, who had an initial virologic response (Lok and McMahon, 2009) . However, there is a time lag between genotypic and phenotypic resistance to lamivudine ranging from 3 to 24 months (Hadziyannis et al., 2000) . In this regard, regular monitoring for genotypic resistance throughout treatment is mandatory to ensure early detection and early rescue of drug resistance (Liaw, 2007) .
SMAP reaction is a unique genotyping technology that can detect genetic mutation under isothermal condition . Unlike the SMAP technology used in the detection of human gene mutation reported previously, this study aims to detect specifi c mutants in a viral population. Adding to the complexity is that the patients undergoing the antiviral therapy oft en contain a subpopulation of viral mutants mixed within the wt viral strains.
Compared with other methods for mutation detection, the SMAP technique has certain advantages. First, high amplifi cation effi ciency of isothermal amplifi cation technology implies the high sensitivity. It has been reported that the detection using SMAP is at least 10-times more sensitive than PCR amplifi cation and sequencing, which is the usual methodology performed today for mutation detection (Kawai et al., 2008) . Th e YVDD SMAP assay in this study could accurately detect as few as 10 3 HBV copies/ml and could discriminate minor mutant populations that comprised only 1% of the wild-type/mutant DNA mixture. Th is indicates that the YVDD SMAP assay can detect resistant strains at a stage prior to viral breakthrough. Moreover, the YVDD SMAP assay detected more mutations than direct sequencing in clinical samples. Th is also suggests that the SMAP method is more sensitive than direct sequencing. Second, in terms of specifi city, the SMAP method could accurately detect single or mixed populations in both plasmid and patient samples. Nonspecifi c amplifi cation was not observed, even in the presence of excess background. In addition, SMAP assay described in this study could be accomplished in less than 1.5 hr, while other methods are still time consuming, requiring several steps such as DNA extraction, PCR, electrophoresis, etc. It has been reported that the SMAP assay can amplify the targets directly from whole blood or blood samples, requiring only a simple heat lysis and denaturation step (Tatsumi et al., 2008) . Th erefore, this method is suitable for routine examination at most medical situation.
Th e advantage of the SMAP assay is based on its mechanism of multiple strand extension co-functioning and selfpriming auto-cycling without temperature change. One limitation of SMAP technology is that it requires careful design of primer sets, however. Th ough the discrimination primer recognizing the target mutation was simultaneously designed at the 3ʹ-end of the FP, and the 5ʹ-end of TP in SMAP format, the background noise derived from the high amplifi cation effi ciency of the SMAP assay still occurred. By using CP, the quality of primer set was improved without compromising amplifi cation effi ciency. We have demonstrated complete suppression of the exponential background amplifi cation through the use of CP in YMDD mutation detection, indicating that multiple blocking strategies could be adopted simultaneously to optimize the design process. One sample detected positive by the SMAP assay showed the pure wt virus by sequencing. Th ough analysis of more clones may detect minor subpopulations of the mutant, this case could not exclude the occurrence of mis-amplifi cation of SMAP reaction. One potential way is to adjust CP. Since the Tm of CP used in this study is 53ʹ, a more rational design is to modify CP by locked Nucleic Acid or peptide nucleic acid to enhance its hybridization effi ciency. In addition, the SMAP method can be applied only to known point mutations at fi xed positions. With several important drug-related mutations described to date, however, one possible SMAP solving method is using a combination of mutation-specifi c primer sets, since SMAP assay has been successfully used in many diff erent mutation profi les like point mutations, in-frame deletions, insertions, and duplications, etc. (Watanabe et al., 2007; Aomori et al., 2009; Miyamae et al., 2010) .
In conclusion, a novel assay based on SMAP method for identifying YVDD mutant viruses in patient samples has been described. Th e SMAP method can accurately and sensitively detect lamivudine-resistant mutants in an easy, rapid, and cost-eff ective way, making the SMAP technology a practical tool for widely use in management of anti-viral therapy.
